Biogen buys the developer of the neurologic preparations Reata for $7,3 billion
Show original
Moscow. July 28. information agency "Interfaks" - the American biotechnological company Biogen Closed joint stock company. The parties expect to close it in the fourth quarter 2023. Reata made significant progress in development the preparations regulating a metabolism and inflammations at serious neurologic diseases, it is noted in the press release. Preparation Skyclarys...